Centene
CENTENE CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$194.8B
Operating marginCalculated
-3.9%
Net assets to total assetsCalculated
26.0%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
-3.9%
Growth (revenue, 4-year average)
★★★★☆position among all companies
11.5%
Capital efficiency
★☆☆☆☆position among all companies
-33.4%
Revenue and profit
Performance, financial position and capital allocation
Centene
Recent performance trends
Centene
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$126.0 billion | US$144.5 billion | US$154.0 billion | US$163.1 billion | US$194.8 billion |
| Operating income | US$1.8 billion | US$1.3 billion | US$2.9 billion | US$3.2 billion | US$-7.6 billion |
| Net income | US$1.3 billion | US$1.2 billion | US$2.7 billion | US$3.3 billion | US$-6.7 billion |
| Total assets | US$78.4 billion | US$76.9 billion | US$84.6 billion | US$82.4 billion | US$76.7 billion |
| Shareholders' equity | US$26.8 billion | US$24.1 billion | US$25.8 billion | US$26.4 billion | US$20.0 billion |
| Net cash provided by (used in) operating activities | US$4.2 billion | US$6.3 billion | US$8.1 billion | US$0.2 billion | US$5.1 billion |
| Net cash provided by (used in) investing activities | US$-3.3 billion | US$-2.9 billion | US$-1.2 billion | US$-1.1 billion | US$0.5 billion |
| Net cash provided by (used in) financing activities | US$1.4 billion | US$-4.2 billion | US$-1.7 billion | US$-2.4 billion | US$-1.6 billion |
| Cash and cash equivalents | US$13.1 billion | US$12.1 billion | US$17.2 billion | US$14.1 billion | US$17.9 billion |
Revenue scale in the same industry
Centene
Insurance carriers: 54 companies · revenue · largest first・FY Dec 2025・Consolidated・Disclosed
- 1 UnitedHealth Group US$447.6B
- 2 Berkshire Hathaway US$371.4B
- 3 The Cigna Group US$274.9B
- 4 Elevance Health US$199.1B
- 5 CenteneThis company US$194.8B
- 6 Humana US$129.7B
- 7 Progressive CORP/OH/ US$87.7B
- … 47 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.8 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$17.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-1.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$5.1 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.3 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$20.0 billion | Consolidated | Disclosed |
| Non-controlling interests | US$80.00 million | Consolidated | Disclosed |
| Net assets | US$20.0 billion | Consolidated | Disclosed |
| Net sales | US$194.8 billion | Consolidated | Disclosed |
| Operating income | US$-7.6 billion | Consolidated | Disclosed |
| Net income | US$-6.7 billion | Consolidated | Disclosed |
| Total assets | US$76.7 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.5 billion | Consolidated | Disclosed |
| Operating margin | -3.9% | Consolidated | Calculated |
| Net assets to total assets | 26.0% | Consolidated | Calculated |
| Net margin | -3.4% | Consolidated | Calculated |
| Return on equity | -33.4% | Consolidated | Calculated |